Clinical Trials Directory

Trials / Completed

CompletedNCT02153476

A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
45 (actual)
Sponsor
Allegro Ophthalmics, LLC · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Evaluate the safety and efficacy of ophthalmic intravitreal injection of ALG-1001 in human subjects with symptomatic focal vitreomacular adhesion

Conditions

Interventions

TypeNameDescription
DRUG2.0mg of ALG-1001
DRUGBalanced Salt Solution

Timeline

Start date
2014-02-01
Primary completion
2015-06-01
Completion
2015-06-01
First posted
2014-06-03
Last updated
2018-12-19
Results posted
2018-07-18

Locations

5 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02153476. Inclusion in this directory is not an endorsement.

A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion (NCT02153476) · Clinical Trials Directory